These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19218889)

  • 1. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides.
    Keller MJ; Herold BC
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S92-5. PubMed ID: 19218889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of semen exposure.
    Mauck CK
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S81-3. PubMed ID: 19218891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for evaluating vaginal microbicides and contraceptives: discovery and early validation.
    Mauck CK
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S73-5. PubMed ID: 19218892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker discovery: validation and decision-making in product development.
    Niedbala RS; Mauck C; Harrison P; Doncel GF
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S76-80. PubMed ID: 19218888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J; Coplan P; Wainberg MA
    Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbicides for multidrug-resistant and multitropic HIV-1.
    D'Cruz OJ; Uckun FM
    Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
    Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbicides: putting women in control.
    Forbes A
    WORLD; 1998 Sep; (89):4-5. PubMed ID: 11365770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.
    Cummins JE; Doncel GF
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S84-91. PubMed ID: 19218890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbicide data show promise.
    AIDS Patient Care STDS; 2009 Mar; 23(3):223-4. PubMed ID: 19480060
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.
    Doncel GF; Clark MR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S10-8. PubMed ID: 21109063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and Perspectives on HIV-1 microbicide development.
    Alexandre KB; Mufhandu HT; London GM; Chakauya E; Khati M
    Virology; 2016 Oct; 497():69-80. PubMed ID: 27429040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection.
    Dhawan D; Mayer KH
    J Infect Dis; 2006 Jan; 193(1):36-44. PubMed ID: 16323129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV.
    Mauck CK; Doncel GF;
    Contraception; 2007 Jun; 75(6):407-19. PubMed ID: 17519146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.
    Fichorova RN; Bajpai M; Chandra N; Hsiu JG; Spangler M; Ratnam V; Doncel GF
    Biol Reprod; 2004 Sep; 71(3):761-9. PubMed ID: 15128598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in microbicide vaginal rings.
    Malcolm RK; Edwards KL; Kiser P; Romano J; Smith TJ
    Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
    J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide.
    D'Cruz OJ; Samuel P; Uckun FM
    Biol Reprod; 2004 Dec; 71(6):2037-47. PubMed ID: 15306558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
    van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
    Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection.
    Abner SR; Guenthner PC; Guarner J; Hancock KA; Cummins JE; Fink A; Gilmore GT; Staley C; Ward A; Ali O; Binderow S; Cohen S; Grohskopf LA; Paxton L; Hart CE; Dezzutti CS
    J Infect Dis; 2005 Nov; 192(9):1545-56. PubMed ID: 16206069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.